SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 701.45 |
| Enterprise Value ($M) | 667.78 |
| Book Value ($M) | 337.90 |
| Book Value / Share | 11.42 |
| Price / Book | 2.08 |
| NCAV ($M) | 271.14 |
| NCAV / Share | 9.16 |
| Price / NCAV | 2.59 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.20 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.40 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 18.13 |
| Current Ratio | 18.30 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 287.49 |
| Assets | 354.25 |
| Liabilities | 16.35 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BCLS Fund III Investments, LP | |||
| 13G/A | Ra Capital Management, L.p. | |||
| 13G/A | Octagon Capital Advisors LP | |||
| 13D/A | Avidity Partners Management LP | 9.90 | 0.25 | |
| 13G | TCG Crossover GP II, LLC | 5.10 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 5.90 | 88.03 | |
| 13G/A | 5AM Partners VII, LLC | 3.50 | -38.92 | |
| 13G | BlackRock, Inc. | 5.60 | 0.00 | |
| 13D/A | Viridian, LLC | 3.72 | 0.00 | |
| 13D/A | Fairmount Funds Management LLC | 9.99 | -0.11 | |
| 13G/A | Third Rock Ventures IV, L.P. | 0.00 | ||
| 13G/A | Citadel Advisors Llc | 0.00 | ||
| 13G/A | Gv 2016, L.p. | 1.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 103,122 | 278,196 | 37.07 | |
| 37,524 | 109,151 | 34.38 | |
| 55,221 | 168,524 | 32.77 | |
| 97,961 | 241,339 | 40.59 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DARE – Daré Bioscience, Inc. | DERM – Journey Medical Corporation |
| DMAC – DiaMedica Therapeutics Inc. | DRMA – Dermata Therapeutics, Inc. |
| DRRX – DURECT Corporation |
Financial data and stock pages provided by
Fintel.io